Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for idiopathic gastroparesis has been reported in the published literature.
3 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.
23 publications have been identified in PubMed for idiopathic gastroparesis. Research spans Clinical Trial Publication (26%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 6 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 5:33 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 4 | 17% |
Patient case studies | 4 | 17% |
Other research | 3 | 13% |
Testing and diagnosis research | 3 | 13% |
Laboratory research | 2 | 9% |
Disease patterns and progression | 1 | 4% |
Kim JH (2026). [PMID: 41959594](https://pubmed.ncbi.nlm.nih.gov/41959594/). *ACG Case Rep J*. [Case Report / Case Series]
Loesch J (2026). [PMID: 40367443](https://pubmed.ncbi.nlm.nih.gov/40367443/). *Am J Gastroenterol*. [Clinical Trial Publication]
Lim JE (2026). [PMID: 41982452](https://pubmed.ncbi.nlm.nih.gov/41982452/). *VideoGIE*. [Diagnostic / Biomarker]
Huang K (2026). [PMID: 41735239](https://pubmed.ncbi.nlm.nih.gov/41735239/). *Neurogastroenterol Motil*. [Diagnostic / Biomarker]
Sarosiek I (2025). [PMID: 41364437](https://pubmed.ncbi.nlm.nih.gov/41364437/). *JAMA Netw Open*. [Clinical Trial Publication]
Khan SZ (2025). [PMID: 39702568](https://pubmed.ncbi.nlm.nih.gov/39702568/). *Surg Endosc*. [Clinical Trial Publication]
Staller K (2025). [PMID: 40976635](https://pubmed.ncbi.nlm.nih.gov/40976635/). *Gastroenterology*. [Review / Meta-Analysis]
Kim GE (2025). [PMID: 39503835](https://pubmed.ncbi.nlm.nih.gov/39503835/). *Curr Gastroenterol Rep*. [Review / Meta-Analysis]
Salehi O (2025). [PMID: 40162405](https://pubmed.ncbi.nlm.nih.gov/40162405/). *World J Gastrointest Surg*. [Clinical Trial Publication]
Nasasra A (2025). [PMID: 40139386](https://pubmed.ncbi.nlm.nih.gov/40139386/). *Clin Nutr ESPEN*. [Other]
AI-curated news mentioning idiopathic gastroparesis
Updated Apr 29, 2026
A recent study explores the clinical characteristics of gastroparesis following anatomical resection for lung cancer, highlighting its implications for patient management. The findings may inform future treatment strategies for affected patients.
FDA has announced its decision to refuse approval for Vanda Pharmaceuticals' new drug application for TRADIPITANT capsules intended to treat symptoms of gastroparesis. This decision follows a hearing request regarding the proposal, impacting the drug's market potential.